2. Anti-infection
  3. Antibiotic
  4. Annamycin

Annamycin is an anthracycline antibiotic with antitumor activity. Annamycin interacts with topoisomerase II, induces double-strand DNA breaks, triggers cell death, and exerts cytotoxic effects. In mice, Annamycin inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma, and prolongs the survival of mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models. Annamycin can be used in research related to melanoma, reticulum cell sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer.

For research use only. We do not sell to patients.

Annamycin

Annamycin Chemical Structure

CAS No. : 92689-49-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Annamycin Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Annamycin is an anthracycline antibiotic with antitumor activity. Annamycin interacts with topoisomerase II, induces double-strand DNA breaks, triggers cell death, and exerts cytotoxic effects. In mice, Annamycin inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma, and prolongs the survival of mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models. Annamycin can be used in research related to melanoma, reticulum cell sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer[1][2][3].

In Vitro

Multidrug-resistant KB-V1, P388/Dox, CEM/Vbl and 8226/R cells exhibit partial loss of cross-resistance to free and multilamellar liposome-encapsulated Annamycin (4 h-72 h)[1].
Annamycin (4.3 min) completely inhibits topoisomerase IIα-mediated DNA cleavage of linearized pBR322 plasmid at an incubation time of 4.3 min[2].
Annamycin (0.1-10 μM; 1 h) potently inhibits P-glycoprotein-mediated efflux in P-gp-expressing cells, with an IC50 of 0.7 μM[2].
Annamycin (4-72 h) circumvents MRP-mediated multidrug resistance in MCF-7, MCF-7/VP, UMCC-1 and UMCC-1/VP cells; it exhibits low resistance indices (1.1, 1.4, 1.3) at 4 and 72 hr exposure durations, with ID50 values ranging from 2.10 to 8.30 μg/mL depending on the cell line and exposure time[3].
Annamycin (5 μg/mL; 1 hr) induces DNA double-strand breaks in MCF-7 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Annamycin Related Antibodies
In Vivo

Free Annamycin (5 mg/kg; i.v.; single dose), Multilamellar liposomal Annamycin (5 mg/kg; i.v.; single dose), and Small unilamellar liposomal Annamycin (5 mg/kg; i.v.; single dose) all inhibit the growth of advanced subcutaneous B16 melanoma, among which the small unilamellar liposome-encapsulated annamycin (S-Ann) exhibits the best efficacy, with a tumor growth inhibition rate (TGI) of 74.4%[1].
Free Annamycin (4 mg/kg; i.v.; single dose), multilamellar liposomal Annamycin (4 mg/kg; i.v.; single dose), and small unilamellar liposomal Annamycin (4 mg/kg; i.v.; single dose) significantly prolong the survival time of mice subcutaneously inoculated with M5076 reticulosarcoma. Among them, small unilamellar liposome-encapsulated Annamycin (S-Ann) shows the highest efficacy, reaching an ILS of 74.4%[1].
Free Annamycin (4 mg/kg; i.v.; single), multilamellar liposomal Annamycin (4 mg/kg; i.v.; single), and small unilamellar liposomal Annamycin (4 mg/kg; i.v.; single) significantly prolong the survival of mice bearing a Lewis lung carcinoma lung metastasis model. Among them, small unilamellar liposome-encapsulated Annamycin (S-Ann) exerts the optimal efficacy, achieving an 85.3 % ILS at low inoculum dose and a 57.6 % ILS at high inoculum dose, along with the highest long-term tumor-free survival rate[1].
Free Annamycin (4 mg/kg; i.v.; weekly; 3 injections), multilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections), and small unilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) all inhibit the growth of subcutaneous KB squamous cell carcinoma xenografts, among which small unilamellar liposome-encapsulated Annamycin (S-Ann) shows the highest efficacy, reaching a TGI of 87.8%[1].
Free Annamycin (4 mg/kg; i.v.; weekly; 3 injections), multilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections), and small unilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) potently inhibit the growth of subcutaneous multidrug-resistant KB-V1 squamous cell carcinoma xenografts. Among them, small unilamellar liposome-encapsulated Annamycin (S-Ann) shows the best efficacy, with a TGI of 92.6% and a 19-fold reduction in tumor growth rate[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 7-8 weeks old, inoculated s.c. with 2×106 viable B16 melanoma cells)[1]
Dosage: 5 mg/kg (Free Annamycin); 5 mg/kg (Multilamellar liposomal Annamycin); 5 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %TGI of 65.0 (Free Annamycin).
Produced a %TGI of 67.6 (Multilamellar liposomal Annamycin).
Produced a %TGI of 74.4 (Small unilamellar liposomal Annamycin).
Was significantly more effective than both Free Annamycin and Multilamellar liposomal Annamycin (P < 0.05, Small unilamellar liposomal Annamycin).
Animal Model: C57BL/6 (male, 7-8 weeks old, inoculated s.c. with 6×105 M5076 reticulosarcoma cells)[1]
Dosage: 4 mg/kg (Free Annamycin); 4 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %ILS of 45.6 (Free Annamycin).
Produced a %ILS of 63.2 (Multilamellar liposomal Annamycin).
Produced a %ILS of 74.4 (Small unilamellar liposomal Annamycin).
Was significantly more effective than doxorubicin (all Annamycin formulations).
Was significantly more effective than Multilamellar liposomal Annamycin and Free Annamycin (P < 0.01 between any two groups, Small unilamellar liposomal Annamycin).
Animal Model: C57BL/6×DBA2 F1 (B6D2F1) (male, 7 weeks old, inoculated i.v. with 3.6×105 or 1×106 Lewis lung carcinoma cells)[1]
Dosage: 4 mg/kg (Free Annamycin); 4 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %ILS of 39.2 with 4/10 long-term survivors (Free Annamycin, low inoculum group).
Produced a %ILS of 73.5 with 7/10 long-term survivors (Multilamellar liposomal Annamycin, low inoculum group).
Produced a %ILS of 85.3 with 8/10 long-term survivors (Small unilamellar liposomal Annamycin, low inoculum group).
Produced a %ILS of 18.7 (Free Annamycin, high inoculum group).
Produced a %ILS of 26.7 (Multilamellar liposomal Annamycin, high inoculum group).
Produced a %ILS of 57.6 (Small unilamellar liposomal Annamycin, high inoculum group).
Was significantly more effective than doxorubicin (all Annamycin formulations).
Was significantly more effective than Multilamellar liposomal Annamycin and Free Annamycin (P < 0.01 between any two groups, Small unilamellar liposomal Annamycin).
Confirmed no tumor presence in long-term survivors (autopsy).
Animal Model: nude (nu/nu) (male, 7-8 weeks old, inoculated s.c. with 0.4×106 KB squamous cell carcinoma cells)[1]
Dosage: 4 mg/kg per injection, total 12 mg/kg (Free Annamycin); 4 mg/kg per injection, total 12 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg per injection, total 12 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; weekly; 3 injections
Result: Produced a %TGI of 78.6 (Free Annamycin).
Produced a %TGI of 83.2 (Multilamellar liposomal Annamycin).
Produced a %TGI of 87.8 (Small unilamellar liposomal Annamycin).
Was significantly more effective than Free Annamycin and doxorubicin (P < 0.05, Small unilamellar liposomal Annamycin).
Animal Model: nude (nu/nu) (male, 7-8 weeks old, inoculated s.c. with 5.8×106 KB-V1 multidrug-resistant squamous cell carcinoma cells)[1]
Dosage: 4 mg/kg per injection, total 12 mg/kg (Free Annamycin); 4 mg/kg per injection, total 12 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg per injection, total 12 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; weekly; 3 injections
Result: Produced a %TGI of 82.3 and reduced tumor growth rate 7-fold compared to controls (Free Annamycin).
Produced a %TGI of 86.4 and reduced tumor growth rate 8-fold compared to controls (Multilamellar liposomal Annamycin).
Produced a %TGI of 92.6 and reduced tumor growth rate 19-fold compared to controls (Small unilamellar liposomal Annamycin).
Was significantly more effective than doxorubicin (P < 0.01, all Annamycin formulations).
Was significantly more effective than Free Annamycin (P < 0.01) and Multilamellar liposomal Annamycin (P < 0.05, Small unilamellar liposomal Annamycin).
Clinical Trial
Molecular Weight

640.37

Formula

C26H25IO11
CAS No.
SMILES

O=C1C2=C(C(C3=CC=CC=C31)=O)C(O)=C(C4=C2O)C[C@@](C(CO)=O)(C[C@@H]4O[C@@]5(O[C@H]([C@@H]([C@H]([C@H]5I)O)O)C)[H])O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Annamycin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Annamycin92689-49-1Antibioticanthracycline antibioticKB-V1 cellsP388/Dox cellsCEM/Vblcells8226/R cellsmelanomareticulum cell sarcomalung cancernon-small cell lung cancersmall cell lung cancersarcoma
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Annamycin
Cat. No.:
HY-13554
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.